Donald Trump nominates man whose firm tripled price of insulin to regulate drug companies | The Independent
Donald Trump’s pick for health secretary, Alex Azar, was previously an executive at a pharmaceutical company that repeatedly raised the prices of its drugs and tripled the cost of its top-selling insulin over the five years he served as a company president, it has emerged.
Mr Trump announced his choice on Monday, tweeting that Mr Azar would be a “star for better healthcare and lower drug prices”.
If Mr Azar becomes Health and Human Services (HHS) secretary, he will oversee a $1tr (£76bn) department responsible for America’s major insurance programmes, including Obamacare, public health, medical research and food and drug safety.
Stealing them blind, out in open sight.